Matinas BioPharma Granted Extension to Restore NYSE American Listing Compliance
Matinas BioPharma Holdings (MTNB) received a notice from the NYSE American stating it is non-compliant due to insufficient stockholders’ equity. As of June 30, MTNB had $1.8 million in stockholders' equity, falling short of the required $2.0 million minimum. The company has also reported losses for multiple consecutive periods. The exchange granted Matinas until October 29, 2027 to regain compliance with listing requirements. If it fails to meet these standards by then, its shares could be delisted from NYSE American. This development adds pressure on the biopharmaceutical company as it seeks financial stability and regulatory alignment. The situation highlights ongoing challenges for small-cap companies in maintaining exchange-mandated capital thresholds amid operational losses.
Topics: financial reporting NYSE American compliance stockholders' equity